BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-21 |
2024-06 |
0 |
N/A |
N/A |
N/A |
2024-05-14 |
2024-03 |
0 |
-0.2 |
N/A |
N/A |
2024-02-12 |
2023-12 |
-0.32 |
-0.22 |
0.1 |
31.25% |
2023-11-08 |
2023-09 |
0 |
-0.29 |
N/A |
N/A |
2023-08-16 |
2023-06 |
-0.37 |
-0.23 |
0.14 |
37.84% |
2023-05-12 |
2023-03 |
-0.31 |
-0.43 |
-0.12 |
-38.71% |
Date |
Firm |
Action |
From |
To |
2023-08-21 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-07-17 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-05-16 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-05-16 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-02-13 |
Oppenheimer |
Upgrade |
|
Outperform |
2022-09-27 |
EF Hutton |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-11-22 |
AHLEM CLARENCE N. |
Officer |
39.62K |
Stock Award(Grant) |
2023-11-08 |
BERMAN RICHARD JAY |
Director |
69.24K |
Stock Award(Grant) |
2024-03-03 |
DO CUONG VIET |
Chief Executive Officer |
0.00 |
Purchase |
2023-11-30 |
GORLIN STEVEN |
Director |
46.36K |
Sale |
2023-11-08 |
HARIRI ROBERT J |
Director |
42.25K |
Stock Award(Grant) |
2023-12-10 |
KIM JOANNE WENDY |
Chief Financial Officer |
44.15K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Ikarian Capital, LLC |
448.56K |
1.93M |
8.62% |
2023-06-29 |
Millennium Management Llc |
334.72K |
1.44M |
6.43% |
2023-06-29 |
Vanguard Group Inc |
178.76K |
770.47K |
3.43% |
2023-06-29 |
Geode Capital Management, LLC |
151.48K |
652.86K |
2.91% |
2023-06-29 |
Blackrock Inc. |
92.58K |
399.02K |
1.78% |
2023-06-29 |
Boothbay Fund Management, LLC |
91.73K |
395.35K |
1.76% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
147.64K |
636.32K |
2.84% |
2023-07-30 |
TIAA-CREF Funds-Equity Index Fund |
72.60K |
342.65K |
1.39% |
2023-05-30 |
Fidelity Extended Market Index Fund |
58.83K |
343.57K |
1.13% |
2023-07-30 |
Fidelity Small Cap Index Fund |
28.95K |
136.63K |
0.56% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
26.69K |
83.01K |
0.51% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
20.89K |
122.00K |
0.40% |
Split |
Date |
2 : 250 |
2019-11-22 |
2 : 250 |
2019-11-08 |
2 : 250 |
2019-08-13 |